There are two timelines that matter when you're considering a trial: the overall study duration (how long the trial runs from first participant to last data collection), and your individual participation period (how long you specifically will be involved). These are often very different numbers, and the one posted on ClinicalTrials.gov is the first one.
What you actually need to know is the second one.
The overall trial duration: phase matters
Phase 1 trials run 1-2 years on average, sometimes shorter for straightforward compounds. The duration is driven by how long it takes to work through the dose escalation sequence, process safety data, and satisfy regulatory reporting requirements.
Phase 2 trials typically run 2-4 years. They're enrolling more participants and collecting more complex efficacy data.
Phase 3 trials are the longest — often 4-8 years, sometimes more. Large populations, multiple sites, multiple countries, long follow-up periods to measure outcomes like survival. A Phase 3 oncology trial measuring overall survival may need to follow participants for 5+ years before the primary endpoint data is complete.
Your participation duration: usually much shorter
Your individual participation in any of the above could be 3 months, 6 months, 12 months, or longer — but it's not the same as the trial's total lifespan. The consent form contains a section that specifies your expected participation period. This is the number that affects your life.
What drives your participation duration:
Treatment duration — how long the protocol requires you to receive the investigational treatment. Some trials have a fixed treatment period (12 weeks of drug); others continue treatment until progression, response, or a study-defined stopping point.
Follow-up period — after treatment ends, most trials continue to monitor participants. A 3-month treatment study might require 12 months of follow-up visits. This is often the part people don't anticipate.
Visit frequency — how often you come in. A study with monthly visits for 12 months is a very different commitment than a study with weekly visits for 12 months, even though the duration is the same.
The question to ask the study team
Ask for the Schedule of Events — the table that shows every visit and procedure from enrollment to end of participation. This exists for every trial; it's part of the protocol. If the coordinator walks you through it, you'll know exactly what you're committing to, week by week.
Also ask: what happens if the trial is stopped early? This is more common than people expect — trials are stopped for positive reasons (treatment works much better than expected, interim analysis triggers early approval) and negative ones (safety signal, futility analysis shows the treatment isn't working). If the trial stops, does your participation end immediately? Is there a transition plan? These questions are worth asking before you need the answers.
When "long" is worth it
A longer participation commitment isn't inherently negative. A 2-year follow-up study that monitors your health closely is also giving you 2 years of structured medical attention. For many participants — particularly those without comprehensive insurance coverage — the level of monitoring they receive during a trial exceeds what they'd get otherwise. That's a legitimate part of the calculation.